Wladimir MietekSzpirt DenmarkRigshospitalet, University of Copenhagen, Dept. of Nephrology, Denmark, Senior Research Consultant

Wladimir MietekSzpirt
CURRICULUM VITAE - Name Wladimir Mietek Szpirt ADDRESS Rigshospitalet, Dept. Of Nephrology, Blegdamsvej 9, 2100 Copenhagen, Denmark PHONE +45 21711709 E mail: Wladimir.mietek.szpirt.01@regionh.dk Born in Poland Szczecin, political refugee status in Denmark 24.10.1969 CITIZENSHIP Danish since 1.7.1976. GRADUATION M.D. University of Copenhagen 1976, SPECIALIST IN INTERNAL MEDICINE AND NEPHROLOGY – 1994. MEMBER OF: European Dialysis and Transplantations Association, since 1979. Danish Society of Nephrology since 1982, International Society of Artificial Organs, since 1984. ISFA - International Society for Apheresis – since it was initiated in 1996, Kyoto. ISFA President May 2015 - May 2017 presently ISFA member of the Board and member of European ISFA, European Vasculitis Society - EUVAS since 1993, Member of the Advisory International Committee of ASFA – American Society of Apheresis, since 2022 Member of the Board World Apheresis Association. Scientific Prize: Danish Society of Nephrology 2014. treatment improvement of Vasculitis kidney patients in Denmark. Work Positions: Rigshospitalet, Nephrology since 1999, Senior Consultant and now Senior Research Consultant since 01.10.2022. Fields of attention Vasculitis and Therapeutic Plasma Exchange
Institution

Day 2 - Monday April 15, 2024

Time Session
3 p.m.
4 p.m.
Late Breaking Clinical Trials Session
LBCT
AlessiaFornoni Chairperson United StatesUniversity of Miami
MichelleRheault Chairperson rheau002@umn.eduUnited StatesUniversity of Minnesota
  • Predicting the Risks of Kidney Failure and Death in Adults With Moderate-to-severe Chronic Kidney Disease (KDpredict)
    PietroRavani Free Communication pravani@ucalgary.caCanadaUniversity of Calgary
  • Plasma Exchange in ANCA Associated Vasculitis GN: Update After Pexivas
    Wladimir MietekSzpirt Speaker wladimir.mietek.szpirt.01@regionh.dkDenmarkRigshospitalet, University of Copenhagen, Dept. of Nephrology, Denmark, Senior Research Consultant
  • EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY: INTERIM RESULTS FROM THE PHASE 3 APPLAUSE-IgAN STUDY
    DanaRizk Free Communication drizk@uabmc.eduUnited StatesUniversity of Alabama at Birmingham
  • SPARSENTAN VS IRBESARTAN IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN): SUBGROUP ANALYSES OF 2-YEAR RESULTS FROM THE PIVOTAL PHASE 3 PROTECT TRIAL
    JonathanBarratt Free Communication United KingdomUniversity of Leicester, Leicester, UK
  • PREGNANCY AMONG WOMEN ON CHRONIC DIALYSIS : THE FRENCH COHORT
    CécileCouchoud Free Communication cecile.couchoud@biomedecine.frFranceREIN registry, Agence de la biomédecine, France
Hall A